NEW YORK – Personalis said on Wednesday that it is partnering with Berry Genomics to facilitate its expansion into China.
Personalis said that it plans to form a wholly owned subsidiary in Shanghai, including a laboratory for local customers to use its ImmunoID NeXT platform, a commercial team to support local customers, and general and administrative functions.
Under the terms of the agreement, Berry Genomics will provide Personalis with certain services and local support.